United States (US)

Epiregulin recombinant protein

Cat No. GTX65075

Application ELISA, Functional Assay, Apuri, Blocking
Reactivity Human
Species Human

Application Note

The ED50 as dertermined by the dose-dependent stimulation of the proliferation of murine balb/3T3 cells is <2.0 ng/ml, corresponding to a specific activity of >5 x10^5 units/mg

Calculated MW

6.0 kDa. ( Note )


Lyophilized powder


0.5 mg/ml solution containing 20 mM PBS, pH 7.4 and 130 mM NaCl.


Reconstitute in sterile water to 0.1–1 mg /ml. The solution can then further diluted to other aqueous solutions. Stored at -20ºC for future use.

Antigen Species


Expression System

E. coli


Purity was assessed by SDS-PAGE (≥97%) and by HPLC (≥97%).


For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.


EREG, Epiregulin


Epiregulin is part of the EGF family. Epiregulin functions as a ligand of EGFR, as well as a ligand of most members of the ERBB (v-erb-b2 oncogene homolog) family of tyrosine-kinase receptors. Epiregulin is expressed mostly in the placenta and peripheral blood leukocytes and in specific carcinomas of the bladder, lung, kidney and colon. Epiregulin stimulates the proliferation of keratinocytes, hepatocytes, fibroblasts and Vascular smooth muscle cells. Epiregulin inhibits the growth of several tumor-derived epithelial cell lines. Human Epiregulin is initially synthesized as a glycosylated 19.0 kDa transmembrane precursor protein, which is processed by proteolytic cleavage to produce a 6.0 kDa mature secreted sequence. Recombinant human EREG produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 50 amino acids and having a molecular mass of 6 kDa.

Research Area